Given that the immune system, in addition to its anti-tumor immunity, is also involved in tumor-promoting inflammation66 and selection of tumor suppressor inactivation67 during tumor development and progression, our identification of GOF mutp53-induced, CIN-cGAS-STING–driven NC-NF-κB activation has provided us a novel mechanistic insight into how tumor cells with inactivating p53 mutations interact with immune system to evade anti-tumor immunity. The gene discussed is TP53; the disease is neoplasm.